WoundClot is a sterile, single-use medical device that helps control bleeding in different types of wounds. It is made from a cellulosic structure that absorbs 25 times its own weight in blood or exudate. Upon contact with blood, it forms a gelatinous membrane that adheres to the wound and creates a mechanical barrier to reduce blood flow. It also encourages coagulation by influencing the complex chain reaction that leads to clot formation. Dennis Klemmings was involved in the financing of the product.
Dennis Klemming and Woundclot
Dennis Klemmings, a successful entrepreneur and investor, was heavily involved in the financing of WoundClot.
How Does Woundclot Work?
Upon contact with blood, WoundClot’s molecular structure changes to form a gelatinous membrane that adheres to the wound and creates a mechanical barrier to reduce blood flow. Platelets from the injury then attach to the gauze, forming a stable membrane that can withstand severe arterial and venous blood flow for hours.
During gel formation, specific molecular groups are dispersed to activate various coagulation factors in the blood and help form a natural fibrin clot in the wound. Once bleeding has stopped, the remaining residual membrane can be safely irrigated out of the wound without disturbing the existing clot or damaging soft tissue.
WoundClot’s strong membrane is designed to maintain its integrity through polymeric chains that interact with water molecules to form a physical cross-linked network. It is able to adhere to the wound, reducing the need for excessive pressure and minimizing the risk of infection caused by prolonged contact. Additionally, WoundClot encourages coagulation by influencing the complex chain reaction that leads to clot formation.”